One study used a dose-tapering approach, allowing participants to gradually reduce their GLP-1RA dose and, in some cases, stop the drug entirely without an increase in mean weight
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have been studied extensively in the last decade and are well suited for the management of T2D in primary and secondary care, owing to their glucose-lowering and weight-loss properties and low intrinsic risk of hypoglycaemia, as well as cardiovascular (CV) benefits [6, 7]
They work by: Slowing stomach emptying Increasing insulin secretion Decreasing appetite Medications in this category include: Semaglutide (brand names: Ozempic, Wegovy) Liraglutide (Saxenda, Victoza) Tirzepatide (Mounjaro technically a dual GIP/GLP-1 agonist) In recent years, theyve been widely used off-label for weight losseven among women trying to conceive
Most authors believe the primary mechanism is still telogen effluvium from rapid weight loss, potential calorie or protein deficiency, and the overall metabolic shock to the body rather than the GLP-1 molecule directly attacking the hair follicle
Ro and Noom have already started partnering with them